Stock comparison
LeMaitre Vascular
BeOne Medicines
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
ONC
BeOne Medicines
Market cap
$33.15B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | ONC | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 62D | LMAT |
| Benjamin Graham | 89A | 75D | LMAT |
| Philip Fisher | 81C | 84C | ONC |
| Peter Lynch | 67B | 75B | ONC |
| Joel Greenblatt | 56D | 49D | LMAT |
| Charlie Munger | 68D | 56D | LMAT |
| Terry Smith | 69D | 60D | LMAT |
Side-by-side metrics
| Metric | LMAT | ONC |
|---|---|---|
| Market cap | $2.23B | $33.15B |
| P/E (TTM) | 37.1x | 107.5x |
| EV/EBIT | 36.6x | 28.9x |
| ROIC (TTM) | 9.43% | 7.73% |
| Gross margin | 72.39% | 87.17% |
| Net margin | 24.35% | 8.93% |
| Revenue CAGR 5y | 12.75% | 45.99% |
| EPS CAGR 5y | 19.04% | 67.36% |
| Debt / Equity | 0.5x | 0.4x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- P/E (TTM)37.1xvs 107.5x+65%
- Net margin24.35%vs 8.93%+63%
- ROIC (TTM)9.43%vs 7.73%+18%
ONC leads on
- Market cap$33.15Bvs $2.23B+93%
- Revenue CAGR 5y45.99%vs 12.75%+72%
- EPS CAGR 5y67.36%vs 19.04%+72%
- EV/EBIT28.9xvs 36.6x+21%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.